Chardan Capital Has Strong Forecast for STOK FY2025 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Analysts at Chardan Capital boosted their FY2025 EPS estimates for shares of Stoke Therapeutics in a research report issued on Wednesday, May 14th. Chardan Capital analyst R. Li now forecasts that the company will earn $0.45 per share for the year, up from their prior estimate of ($1.75). Chardan Capital has a "Buy" rating and a $24.00 price target on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share.

A number of other equities analysts have also commented on STOK. HC Wainwright decreased their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Stoke Therapeutics has an average rating of "Buy" and a consensus target price of $23.20.

Stoke Therapeutics Trading Down 1.5%

Shares of NASDAQ:STOK traded down $0.14 during trading on Monday, reaching $9.36. The company had a trading volume of 471,276 shares, compared to its average volume of 711,112. The company has a fifty day moving average of $8.26 and a two-hundred day moving average of $9.87. The stock has a market capitalization of $511.03 million, a P/E ratio of -4.46 and a beta of 1.20. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. The firm had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC boosted its position in Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after buying an additional 5,084 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Stoke Therapeutics during the 4th quarter valued at $63,000. AlphaQuest LLC purchased a new stake in Stoke Therapeutics during the 1st quarter valued at $72,000. US Bancorp DE boosted its position in Stoke Therapeutics by 9,743.9% during the 1st quarter. US Bancorp DE now owns 11,222 shares of the company's stock valued at $75,000 after buying an additional 11,108 shares during the period. Finally, Fox Run Management L.L.C. purchased a new stake in Stoke Therapeutics during the 1st quarter valued at $92,000.

Insider Activity at Stoke Therapeutics

In related news, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now owns 148,253 shares of the company's stock, valued at approximately $1,285,353.51. This trade represents a 6.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Barry Ticho sold 3,884 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares in the company, valued at approximately $554,550.54. This represents a 5.72% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,532 shares of company stock valued at $143,332. Insiders own 11.30% of the company's stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.